Lumos Pharma Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Lumos Pharma are completely uncorrelated.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Lumos Pharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy primary indicators, Lumos Pharma is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 56 M |
Lumos |
Lumos Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Lumos Pharma on November 18, 2024 and sell it today you would earn a total of 100.00 from holding Lumos Pharma or generate -100.0% return on investment over 90 days. Lumos Pharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Lumos, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Lumos Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Lumos Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lumos Pharma, and traders can use it to determine the average amount a Lumos Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LUMO |
Based on monthly moving average Lumos Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lumos Pharma by adding Lumos Pharma to a well-diversified portfolio.
Lumos Pharma Fundamentals Growth
Lumos Stock prices reflect investors' perceptions of the future prospects and financial health of Lumos Pharma, and Lumos Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Lumos Stock performance.
| Return On Equity | -1.73 | |||
| Return On Asset | -0.7 | |||
| Operating Margin | (10.52) % | |||
| Current Valuation | 24.19 M | |||
| Shares Outstanding | 8.65 M | |||
| Price To Earning | (2.37) X | |||
| Price To Book | 7.64 X | |||
| Price To Sales | 17.02 X | |||
| Revenue | 2.05 M | |||
| EBITDA | (36.57 M) | |||
| Cash And Equivalents | 79.51 M | |||
| Cash Per Share | 9.49 X | |||
| Total Debt | 585 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 0.57 X | |||
| Cash Flow From Operations | (31.09 M) | |||
| Earnings Per Share | (4.28) X | |||
| Total Asset | 40.64 M | |||
| Retained Earnings | (161.52 M) | |||
| Current Asset | 115.78 M | |||
| Current Liabilities | 14.4 M | |||
Things to note about Lumos Pharma performance evaluation
Checking the ongoing alerts about Lumos Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Lumos Pharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Lumos Pharma is not yet fully synchronised with the market data | |
| Lumos Pharma has some characteristics of a very speculative penny stock | |
| Lumos Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 2.05 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 1.52 M. | |
| Lumos Pharma currently holds about 79.51 M in cash with (31.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 9.49. | |
| Roughly 33.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Lumos Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Lumos Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Lumos Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Lumos Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Lumos Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Lumos Pharma's stock. These opinions can provide insight into Lumos Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Other Consideration for investing in Lumos Stock
If you are still planning to invest in Lumos Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Lumos Pharma's history and understand the potential risks before investing.
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |